Syndicated Research Report Pharmaceuticals

Omalizumab Biosimilars Market

Size, Share & Industry Analysis, By Delivery Presentation (Prefilled Syringe, Autoinjector), By Therapeutic Indication (Chronic Spontaneous Urticaria, Allergic Asthma, Chronic Rhinosinusitis with Nasal Polyps, IgE-Mediated Food Allergy), By Treatment Setting (Hospital Outpatient Departments, Specialist Allergy Clinics, Community and Specialty Pharmacies), By Procurement Channel (Public Tenders and Hospital Procurement, Private Insurance Formularies, Direct and Self-Pay Purchasing), and Regional Forecast, 2026-2034

Report ID 24LS-15053
Pages 116
Last Updated
Author 24LifeSciences Research Team
Industry Pharmaceuticals
Starting from $995 USD

Market Overview

2025 Market SizeUSD 623.5 MnBase year
2026 EstimateUSD 683.2 MnEstimated year
2034 ForecastUSD 1420.0 MnForecast value
CAGR9.6%2026–2034
Largest RegionEurope2025

Omalizumab Biosimilars Market Overview

The global Omalizumab Biosimilars Market reached USD 623.5 million in 2025 and is estimated at USD 683.2 million for 2026. The publisher-derived series projects USD 1.42 billion by 2034, equivalent to a 9.6% CAGR from 2026 through 2034.

May 2024European authorisation of OmlycloEuropean Medicines Agency
March 2025First U.S. interchangeable omalizumab biosimilar approvalFDA
26European countries selling Omlyclo by September 2026Celltrion
363 millionPeople affected by asthma worldwide in 2023World Health Organization

Omalizumab biosimilars are anti-immunoglobulin E monoclonal antibodies referencing Xolair and developed to meet regulatory comparability requirements. The European Medicines Agency authorised Celltrion’s Omlyclo in May 2024 for allergic asthma, chronic spontaneous urticaria and severe chronic rhinosinusitis with nasal polyps. In March 2025, the FDA approved Omlyclo as the first U.S. interchangeable omalizumab biosimilar, with a broader American indication set that also includes IgE-mediated food allergy.

Commercial launches followed the 2024 European authorisation on different national timetables. Celltrion began European availability in Norway in September 2025, expanded into major European markets later that year, and launched its 300 mg presentation in Germany, the United Kingdom and France during 2026. Its U.S. commercial launch followed on 5 October 2026, well after the initial FDA authorisation, demonstrating why an approval date and a booked sales date should not be treated as identical.

Novartis and Genentech continued selling the Xolair originator in 2025 while biosimilar entrants sought formulary access. Novartis reported USD 1.723 billion of 2025 Xolair revenue from its continuing operations, while Amneal cited USD 4.1 billion of U.S. Xolair sales in the twelve months ended July 2025. Those figures describe originator exposure and are not counted as biosimilar sales. The publisher’s 2025 biosimilar value instead provides the market-series starting point, with marketed supply and product-specific collaborations forming the defined commercial boundary.

Teva and Kashiv filed new omalizumab biosimilar applications during 2025–2026. Teva announced FDA and EMA acceptance of its proposed omalizumab biosimilar applications in March 2026, while Kashiv’s ADL-018 program progressed through a U.S. filing and an accepted European application. CuraTeQ disclosed positive Phase III results for BP11 in April 2026. Additional approvals may enlarge the addressable payer base, but the clinical evidence, national tender rules and immunogenicity monitoring remain central to adoption.

Source: EMA Omlyclo authorisation; Celltrion U.S. launch; Novartis product sales; WHO asthma facts.

Key Takeaways: Omalizumab Biosimilars Market

  • Base-year market size: The publisher-defined global category generated USD 623.5 million in 2025, including the commercial biosimilar value boundary used for this forecast.
  • Forecast and CAGR: The 2034 projection is USD 1.42 billion, with 9.6% annualised expansion during 2026–2034.
  • Leading presentation: Prefilled Syringes represented an estimated ~92% of 2025 revenue, reflecting early Omlyclo launches in syringe formats.
  • Leading indication: Chronic Spontaneous Urticaria represented an estimated ~62% of 2025 revenue, supported by the original CT-P39 clinical program.
  • Largest region: Europe accounted for an estimated ~51% of 2025 revenue, following its May 2024 authorisation and September 2025 commercial rollout.
  • Key growth drivers: European country launches, the October 2026 U.S. entry, 300 mg presentations, payer tenders and additional regulatory filings support future uptake.
  • Competitive landscape: Celltrion markets Omlyclo; Teva, Kashiv, Amneal, Alvotech, Advanz Pharma, CuraTeQ and BiosanaPharma participate in competing programs.
  • Report coverage: The forecast evaluates four exclusive dimensions, five geographic regions and national commercialisation conditions through 2034.

Report Scope & Market Segmentation

Manufacturer-level sales of approved omalizumab biosimilars and identifiable in-scope development, supply or commercialisation receipts, excluding originator Xolair sales and unrelated asthma therapies.

Report AttributeCoverage
Base Year2025
Estimated Year2026
Forecast Period2026–2034
Market MeasurementRevenue, USD million/billion
By Delivery PresentationPrefilled Syringe; Autoinjector
By Therapeutic IndicationChronic Spontaneous Urticaria; Allergic Asthma; Chronic Rhinosinusitis with Nasal Polyps; IgE-Mediated Food Allergy
By Treatment SettingHospital Outpatient Departments; Specialist Allergy Clinics; Community and Specialty Pharmacies
By Procurement ChannelPublic Tenders and Hospital Procurement; Private Insurance Formularies; Direct and Self-Pay Purchasing
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Selected CountriesUnited States; Canada; Norway; Germany; United Kingdom; Japan; South Korea; Australia; Brazil; Saudi Arabia
Key Market PlayersCelltrion, Inc.; Teva Pharmaceutical Industries Ltd.; Kashiv BioSciences LLC; Amneal Pharmaceuticals, Inc.; Alvotech; Advanz Pharma; CuraTeQ Biologics; BiosanaPharma

Market Definition & Revenue Boundaries

The revenue boundary includes finished omalizumab biosimilar medicines supplied to wholesalers, hospitals and pharmacy networks, and development or commercialisation receipts attributable specifically to a biosimilar candidate. It excludes Xolair originator sales, all non-omalizumab anti-IgE medicines, diagnostic testing and physician administration fees. Pipeline products are described separately from approved and commercially available products; filings and partnerships do not constitute regulatory authorisations.

The 2025 and 2034 monetary endpoints are publisher values, not a bottom-up audited aggregation of Celltrion shipments or competitor royalties. The 2026 estimate and 2026–2034 CAGR follow the mathematical interpolation of those endpoints. For product status, Omlyclo is approved in the EU and U.S., whereas AVT23/ADL-018, Teva’s proposed candidate and CuraTeQ BP11 remain investigational until an agency grants a marketing authorisation.

Omalizumab Biosimilars Market Dynamics

Drivers Impact Analysis*

Market DriversImpact RankCAGR Contribution (%)2026–20282029–20312032–2034
U.S. interchangeability and European approval supporting substitutionHigh+3.70%HighHighMedium
Expansion of 300 mg syringe and autoinjector presentationsHigh+3.10%HighMediumMedium
Public tender adoption across European healthcare systemsMedium-High+2.50%HighHighMedium
Additional omalizumab biosimilar applications entering regulatory reviewMedium+2.20%MediumHighHigh
Asthma and urticaria treatment demand in existing eligible patientsLow-Medium+1.70%MediumMediumHigh
Others (Japan rollout, Brazilian launch, partner supply agreements)Low+1.20%MediumMediumMedium

Restraints Impact Analysis*

Market RestraintsImpact RankCAGR Contribution (%)2026–20282029–20312032–2034
Net price reductions from national tenders and rebatesHigh-2.10%HighHighHigh
Manufacturing comparability and pharmacovigilance costsMedium-High-1.40%HighMediumMedium
Patent disputes and formulary restrictions delaying entryMedium-0.80%MediumMediumLow
Others (device training, safety warnings, procurement delays)Low-0.50%MediumLowLow

*CAGR contribution shows the percentage points each factor adds to or removes from the 9.6% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

Regulatory approval turns an established IgE mechanism into biosimilar prescribing

The FDA approved Omlyclo on 9 March 2025 and granted interchangeability with Xolair across four U.S. indications. The European Commission had authorised the product in May 2024, permitting initial European market entry. National substitution rules, payer formularies and physician experience determine whether those legal permissions translate into dispensed prescriptions. Because Xolair had been used for allergic asthma since 2003, clinicians already understand its dosing by body weight and IgE levels, reducing the need to establish a new therapeutic mechanism.

Wider dosage options change the number of injections per treatment visit

Celltrion obtained a U.S. 300 mg/2 mL prefilled-syringe approval in December 2025 after earlier 75 mg and 150 mg approvals. European launches of the 300 mg strength began in Germany, France and the United Kingdom in 2026, with both syringe and autoinjector options. A patient prescribed 300 mg can receive one higher-strength injection instead of multiple smaller injections where the label permits, potentially reducing appointment time and device handling. Dosing convenience can influence tender decisions even when clinical biosimilarity is already established.

Large reference-product spending attracts rival development programs

Amneal disclosed about USD 4.1 billion in U.S. Xolair sales for the twelve months ending July 2025 when announcing the ADL-018 BLA submission. Alvotech, Kashiv and Advanz progressed AVT23 into UK and European application reviews during 2025. Teva reported dual FDA and EMA filing acceptance in March 2026, and CuraTeQ released a 608-patient Phase III result in April 2026. Kashiv’s 2025 application and Teva’s 2026 submissions added documented regulatory review programs, while manufacturing comparability and intellectual-property timelines can postpone commercial supply.

Safety requirements and immunogenicity monitoring constrain automatic switching

The U.S. omalizumab label carries an anaphylaxis boxed warning and requires clinical judgement on initiation, observation and subsequent self-administration. The FDA interchangeability designation does not remove state pharmacy-substitution requirements or insurer restrictions. EMA evaluation of Omlyclo included comparative analytical data and a chronic urticaria efficacy study through 40 weeks. Pharmacovigilance, device training and product traceability therefore remain purchasing criteria, especially for pediatric asthma and food-allergy use. Hospitals also require batch-level documentation and clear escalation procedures for suspected anaphylaxis, because a lower procurement price does not remove the need for prompt emergency management.

Tender pricing can expand treatment volumes while reducing unit revenue

Celltrion reported Omlyclo availability in 26 European countries by September 2026 and substantial penetration in Spain. European national tenders can rapidly shift supplier choice when an interchangeable or biosimilar medicine meets clinical and procurement requirements. The United States began commercial availability in October 2026, with access influenced by pharmacy benefit managers rather than a single national tender. A growing treated population can coexist with lower net revenue per injection when tender discounts and rebates deepen.

Sources: FDA approval letter; EMA Omlyclo; Celltrion; Amneal; Teva; Alvotech.

Approved Biosimilars and Clinical Development Pipeline

Omlyclo is the approved omalizumab biosimilar with broad international registrations, while AVT23/ADL-018 and other candidates remain under review or clinical development. The reference Xolair provides the established efficacy and safety profile against which comparative programs are assessed. The 2025 ADL-018 study assessed weekly itch severity at week twelve, while Omlyclo’s pivotal program followed patients with urticaria for forty weeks.

ProgramDeveloper / partnerStatus at October 2026Clinical or commercial evidence
Omlyclo / CT-P39CelltrionApproved EU, U.S., Australia and JapanFDA interchangeability; 75, 150 and 300 mg options
AVT23 / ADL-018Kashiv; Alvotech; Advanz; AmnealRegulatory applications under review600-patient confirmatory CSU study
Teva omalizumab candidateTeva Pharmaceutical IndustriesFDA and EMA submissions accepted March 2026Biosimilarity assessment pending
BP11CuraTeQ Biologics / AurobindoInvestigational Phase III completed608 participants across Europe and India

Omlyclo’s U.S. label covers moderate-to-severe allergic asthma from age six, chronic spontaneous urticaria from age twelve, nasal polyps in adults and IgE-mediated food allergy from age one. EMA indications and age restrictions are not identical to those in the United States. A prescribing decision must follow the locally authorised product information, including the anaphylaxis warning and restrictions on emergency allergy treatment.

The AVT23 program achieved positive confirmatory efficacy results in chronic spontaneous urticaria during 2025. The trial enrolled 600 patients, with efficacy assessed in 400 participants receiving the confirmatory 300 mg dose; the primary endpoint was change in weekly itch severity at week twelve. Alvotech announced UK application acceptance in March and EMA acceptance in October of that year, but neither event should be presented as an approval. Teva’s March 2026 filing milestone and CuraTeQ’s April 2026 Phase III readout similarly support prospective competition rather than existing sales of those investigational candidates. CuraTeQ reported that BP11 met its primary efficacy endpoints across a multicountry trial of 608 patients and identified allergic asthma and nasal polyps as potential future submission indications.

Omalizumab Biosimilars Market Segmentation by Delivery Presentation

Report Segmentation
By Delivery Presentation

Omalizumab biosimilar products are supplied as ready-to-use subcutaneous injections. Device choice is commercially meaningful because body-weight and IgE-based dosing can require more than one injection, while home administration depends on training and local labelling.

Leading Format

Prefilled Syringe

Prefilled Syringes represented an estimated ~92% of 2025 revenue. The EU approved Omlyclo in syringe presentations in May 2024, and the U.S. cleared 75 mg and 150 mg prefilled syringes in March 2025. The 300 mg syringe extension followed in December 2025 in the United States. Syringe availability supports hospital outpatient and allergy-clinic workflows where observation after injection may be required.

Emerging Device

Autoinjector

Autoinjectors accounted for a smaller initial commercial base. Celltrion gained a Korean autoinjector approval in December 2025 and introduced both syringe and autoinjector presentations in European 300 mg launches during 2026. These devices can simplify self-injection for suitable patients after supervised training, although local safety guidance still governs initiation and observation. Competition may shift toward dose flexibility rather than molecular differentiation.

Device mix is expected to broaden as more national regulators clear autoinjector presentations and as manufacturers support home administration. Procurement teams also evaluate packaging, cold-chain handling, needle protection and patient support when comparing clinically similar products. For omalizumab, the weight-and-IgE dosing schedule may require multiple units per visit, making pack configuration an operational concern for hospital pharmacies.

Omalizumab Biosimilars Market Segmentation by Therapeutic Indication

Report Segmentation
By Therapeutic Indication

Indication-specific uptake is governed by each jurisdiction’s label and the specialty pathway through which patients enter biologic care. The FDA and EMA permit overlapping but not identical sets of uses, and revenue is assigned to the clinical reason for treatment rather than counted twice.

Largest Indication

Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria represented an estimated ~62% of 2025 revenue. The pivotal Omlyclo comparative trial enrolled patients with persistent urticaria despite antihistamine treatment, giving dermatology and allergy prescribers a direct biosimilar evidence base. Celltrion’s September 2025 EADV activities reinforced physician education in this indication. Routine follow-up visits allow clinicians to monitor symptom control and injection tolerance.

Established Indication

Allergic Asthma

Severe allergic asthma provides a substantial eligible population, but not every patient with asthma needs anti-IgE treatment. WHO counted 363 million people with asthma in 2023, while omalizumab eligibility depends on severity, allergic sensitisation and inadequate control with standard inhaled therapy. Respiratory specialists may switch suitable patients after assessing local substitution rules and reimbursement.

Specialist Indication

Chronic Rhinosinusitis with Nasal Polyps

Adult patients with severe nasal polyps and inadequate response to nasal corticosteroids can receive omalizumab under the approved indication. ENT and allergy teams evaluate recurrence, surgery history and corticosteroid burden before selecting biologic therapy. As more hospitals adopt biosimilar formularies, this indication offers additional treatment volume without requiring a different molecular mechanism.

U.S.-Specific Opportunity

IgE-Mediated Food Allergy

The FDA expanded reference omalizumab use to food allergy in February 2024 for patients aged one year and older, and Omlyclo’s U.S. authorisation includes that indication. It reduces the risk of reactions after accidental exposure but does not replace allergen avoidance or emergency epinephrine. Specialist follow-up and patient education limit rapid substitution without clinical review.

National labels, patient age, severity and payer criteria create different adoption curves by indication. Urticaria remains the base-year leader, while allergic asthma and food allergy can add incremental volume as U.S. commercial availability matures.

Omalizumab Biosimilars Market Segmentation by Treatment Setting

Report Segmentation
By Treatment Setting

Treatment setting reflects where omalizumab is prescribed, administered and dispensed, not a separate clinical indication. A prescription belongs to one setting in the private revenue model, preventing double counting when patients move from specialist initiation to home injections.

Largest Setting

Hospital Outpatient Departments

Hospital outpatient departments represented the leading treatment setting in the 2025 private allocation. Hospitals supervise first administrations and manage patients with complex allergic disease, including those at risk of anaphylaxis. Formularies may adopt biosimilars after pharmacy-and-therapeutics review, and national tenders can influence the preferred manufacturer across multiple hospital sites.

Specialist Channel

Specialist Allergy Clinics

Allergists, pulmonologists and dermatologists prescribe omalizumab after confirming eligibility for severe asthma or antihistamine-refractory urticaria. Specialist clinics conduct baseline assessments, review dose intervals and provide injection education. These practices may expand biosimilar use after comparative clinical data and safety surveillance establish confidence in switching.

Dispensing Channel

Community and Specialty Pharmacies

Community and specialty pharmacies coordinate ongoing supply when the local label permits trained patients to self-administer. In the United States, the October 2026 launch created a new pharmacy-benefit pathway for Omlyclo, while European systems use different mixes of retail dispensing and hospital purchasing. Cold-chain logistics and refill continuity remain important to treatment persistence.

More high-dose syringes and autoinjectors may transfer repeat administrations toward pharmacies and supervised home use. Hospitals remain important for initial dosing, serious allergic reactions and patients whose clinical circumstances require observation.

Omalizumab Biosimilars Market Segmentation by Procurement Channel

Report Segmentation
By Procurement Channel

Procurement contracts determine the net price received by biosimilar suppliers and the pace of uptake in each healthcare system. Tender purchases, private-plan formularies and direct patient payment are assigned separately to avoid counting the same dispensed medicine across channels.

Largest Procurement Route

Public Tenders and Hospital Procurement

Public tenders and hospital procurement represented the largest modeled channel in 2025, led by European institutions. Celltrion’s rollout across 26 European countries by September 2026 indicates a broad contracting footprint, but contract awards and patient prescriptions are different metrics. Hospitals can prefer products that combine clinical comparability with high-dose and device options.

Insurance Route

Private Insurance Formularies

Private insurance formularies are especially relevant in the United States, where Omlyclo launched commercially in October 2026. Pharmacy benefit managers negotiate preferred status, rebates and prior-authorisation conditions, and state rules determine whether pharmacists may substitute an interchangeable biosimilar. Teva and Amneal are pursuing later entries that may change bargaining leverage.

Cash Route

Direct and Self-Pay Purchasing

Direct purchasing is a smaller modeled route because repeated anti-IgE injections can be expensive without reimbursement. Patients who lack access to hospital procurement or insured coverage may defer treatment despite clinical eligibility. Lower biosimilar prices can increase cash-pay access, but supervised initiation and monitoring remain medical requirements.

Tender discounting can lift patient volume while depressing unit revenue, so the procurement mix matters to the 2026–2034 value forecast. Local registration, payer negotiations and supply reliability are more decisive than list prices alone.

Omalizumab Biosimilars Market Regional Analysis

Omalizumab biosimilar sales began in different calendar years across Europe, Asia-Pacific, North America and Latin America. The 2025 private regional allocation assigns each shipment once to its destination market and reserves no sales for unapproved pipeline candidates.

North America

New U.S. commercial phase - FDA interchangeability since March 2025

North American access differs between the United States and Canada. The FDA approved Omlyclo in March 2025 but Celltrion did not announce U.S. commercial availability until October 2026, so regulatory clearance should not be treated as a full 2025 U.S. sales year. The initial U.S. 75 mg and 150 mg presentations were followed by a 300 mg authorisation in December 2025. Canada had already authorised Omlyclo and subsequently expanded higher-dose device options. American payer contracts and state pharmacy-substitution rules will shape future volume, while Canadian provincial formularies may apply their own biosimilar switching policies. Reference Xolair expenditure provides a large addressable pool, but the originator’s revenue is outside this biosimilar boundary.

Priority country signals

United States

Selected market signal

Celltrion began commercial Omlyclo distribution on 5 October 2026, after receiving FDA interchangeability in March 2025. The launch covers asthma, chronic urticaria, nasal polyps and IgE-mediated food allergy. Amneal had filed a proposed Kashiv-developed alternative in September 2025, while Teva disclosed FDA acceptance in March 2026. Competition for preferred formulary status will determine actual dispensing volumes.

Source: Celltrion USA.

Canada

Selected market signal

Celltrion reported Canadian approval of Omlyclo 300 mg prefilled-syringe and autoinjector options in January 2026. The higher-dose products widen treatment choice for chronic urticaria and allergic asthma while preserving local prescribing requirements. Alvotech and Advanz have contracted Canadian commercial rights for the investigational AVT23 program, which still requires approval before routine sales.

Source: Celltrion Canada update.

Europe

Largest region - ~51% of 2025 revenue

Europe represented an estimated ~51% of global 2025 revenue, supported by the May 2024 Omlyclo authorisation and early commercial availability. Celltrion launched in Norway in September 2025 and expanded across other European markets later that year. In November 2025, the European Commission approved a 300 mg line extension, enabling the 2026 launch of high-dose presentations in Germany, the United Kingdom and France. European procurement relies heavily on national health systems, hospital formularies and tender negotiations. The EMA accepted AVT23’s application in October 2025, while Teva’s candidate entered review in March 2026. Both remain prospective competitors rather than additional authorised suppliers at the dates of those announcements.

Priority country signals

Norway

Selected market signal

Celltrion selected Norway for the first European commercial availability of Omlyclo in September 2025, after the EU-wide authorisation in May 2024. National procurement processes and specialist allergy clinics can shift use from Xolair to the approved biosimilar. The Norwegian launch provides a documented 2025 commercial starting point for Europe rather than merely a marketing authorisation.

Source: Celltrion Europe launch.

Germany and United Kingdom

Selected market signal

Celltrion began introducing 300 mg Omlyclo presentations in Germany and the United Kingdom during 2026, adding both prefilled syringes and autoinjectors. The higher dose reduces the number of injections needed for some regimens. Advanz Pharma separately holds regional commercial rights for investigational AVT23, whose UK application was accepted in March 2025 and remains subject to regulatory review.

Source: Celltrion 300 mg launch.

Asia-Pacific

Established Korean approvals - Japan approval March 2026

Asia-Pacific accounts for a substantial early-market allocation because Celltrion is headquartered in South Korea and secured Korean regulatory clearances before several Western commercial launches. The company subsequently added autoinjector presentations in December 2025, providing an additional route for suitable patients. Japan approved Omlyclo in March 2026, with market introduction dependent on local pricing and distribution. Australia registered the product in November 2024 and published its public assessment in August 2025. India contributes investigational supply through CuraTeQ’s BP11 program, whose 608-patient Phase III study spanned Europe and India. Country differences in insurance coverage, specialist access and manufacturing capacity prevent uniform biosimilar penetration across the region.

Priority country signals

Japan

Selected market signal

Japan’s Ministry of Health, Labour and Welfare authorised Celltrion’s omalizumab biosimilar in March 2026 for bronchial asthma, chronic urticaria and seasonal allergic rhinitis. The Japanese indication set differs from the U.S. food-allergy label. Commercial uptake will depend on official reimbursement pricing, local prescriber education and the timing of the product’s launch after approval.

Source: Celltrion Japan approval.

Australia

Selected market signal

Australia’s Therapeutic Goods Administration registered Omlyclo on 26 November 2024 as a new biosimilar medicine. The published indication set covers allergic asthma, chronic urticaria and nasal polyps, subject to Australian product information. The agency’s 2025 assessment documented the review timeline and comparative evidence, supporting pharmacist and clinician evaluation of the product’s regulatory status.

Source: TGA Omlyclo registration.

Latin America

Brazil commercial launch - November 2025

Latin America entered the commercial omalizumab biosimilar period through Brazil, where Celltrion announced the first Omlyclo launch in November 2025. The initial 150 mg presentation was followed by plans for additional strengths, which can broaden prescriber choice in allergy and dermatology clinics. National procurement systems and private insurers determine access across a region with substantial differences in purchasing power. Kashiv also signed a Latin American licensing and supply agreement with Brazil’s Crist - lia for its proposed ADL-018 product in 2025. That agreement establishes future distribution rights but does not establish approval or commercial sales for ADL-018. Currency changes, cold-chain capacity and payer price negotiations may constrain revenue despite increasing treated patient numbers.

Priority country signals

Brazil

Selected market signal

Celltrion announced Omlyclo’s Brazilian launch on 27 November 2025, beginning with the 150 mg presentation for chronic urticaria and related approved uses. The company promoted the medicine to local allergy specialists through the Brazilian Association of Allergy and Immunology. Kashiv separately announced a Crist - lia licensing agreement for ADL-018, which remained investigational at that stage.

Source: Celltrion Brazil launch.

Regional partners

Selected market signal

Kashiv’s September 2025 announcement of a Latin American supply agreement with Crist - lia describes a potential second-wave route for omalizumab biosimilars. Distribution rights do not eliminate the need for national marketing authorisations. Private hospital networks and specialty pharmacies in neighboring countries may use Brazilian clinical and commercial experience when considering subsequent biosimilar procurement.

Source: Kashiv partnership news.

Middle East & Africa

Pipeline-linked territory - No broad 2025 launch evidence

Middle East and African countries have a less mature omalizumab biosimilar commercial footprint than Europe and Asia-Pacific. In August 2025, Kashiv announced an agreement with MS Pharma covering a proposed ADL-018 biosimilar in Middle East and North Africa markets. The agreement is a development and commercialisation arrangement, not evidence that the candidate had already received local marketing authorisation. National health systems differ in the extent of biologic reimbursement and access to specialist asthma care. Public procurement may eventually favour lower-cost anti-IgE medicines where clinical comparability is accepted, while fragmented distribution and refrigeration requirements can delay launches. No region-wide Omlyclo sales figure was disclosed in the official materials reviewed, so regional share remains a private allocation rather than a supplier-audited estimate. Health ministries must also decide whether to fund long-term biologic therapy for severe asthma or urticaria, and local import authorisations can delay supply even when a manufacturer has a regional distribution partner.

Priority country signals

Middle East and North Africa

Selected market signal

Kashiv listed an August 2025 license-and-supply agreement with MS Pharma for ADL-018 across Middle East and North Africa markets. The proposed biosimilar was still undergoing regulatory assessment, so the agreement cannot be treated as a marketed medicine in every covered country. Future uptake depends on national approvals, hospital tenders, local pharmacovigilance and distribution capacity.

Source: Kashiv licensing updates.

Reimbursement, Pricing & Market Access

Biosimilar reimbursement varies between national tenders, pharmacy benefits and private patient payments. Approval, availability and formulary preference are separate events, each with a different impact on supplier revenue. In the United States, FDA authorisation preceded commercial distribution by nineteen months.

Market access mechanism2025–2026 eventClinical or procurement consequenceRevenue implication
U.S. interchangeabilityFDA designation March 2025State substitution and payer rules still applyAccess expands after October 2026 launch
EU national tendersNorway launch September 2025Public procurement can select preferred supplierVolume gain may offset discounts
High-dose device accessEU 300 mg approval November 2025Fewer injections for selected regimensSupports device-based differentiation
Canadian dose expansion300 mg approvals January 2026Additional syringe and autoinjector optionsWider covered presentation range

The FDA interchangeability decision permits substitution subject to state pharmacy laws and prescriber instructions. Celltrion’s U.S. commercial launch in October 2026 means reimbursement discussions can begin translating into filled prescriptions. Specialty pharmacies may coordinate authorization, cold-chain shipping and injection training for eligible patients, while clinics remain responsible for clinical monitoring after treatment initiation.

European tender contracting can rapidly redirect public purchasing after a biosimilar becomes available. Omlyclo’s expansion to 26 European countries by September 2026 demonstrates a broad commercial footprint, but national discounts are not interchangeable with manufacturer list prices. High-dose syringe and autoinjector presentations offer procurement committees an additional operational factor beyond drug acquisition cost.

Canada and Australia use their own regulator-approved product information and payer processes. The TGA registered Omlyclo in November 2024, and Celltrion later obtained Canadian 300 mg presentation approvals. Australia’s August 2025 public assessment documented the comparative quality and clinical review, giving local decision-makers a detailed regulatory basis for considering the new biosimilar. These authorisations create opportunities for local reimbursement decisions, yet no uniform global substitution mandate exists for omalizumab products.

Source: FDA Omlyclo approval; Celltrion European launch; TGA Omlyclo.

Regulatory, Patent & Pipeline Landscape

Regulators require extensive analytical and clinical comparability for an omalizumab biosimilar, and a filing acceptance does not confer permission to market a product. The distinction is especially important while second-wave candidates remain under review. Kashiv’s U.S. submission in September 2025, the EMA acceptance of AVT23 in October 2025 and Teva’s March 2026 dual filing acceptance establish three dated review milestones without demonstrating approval of those investigational products.

DateRegulatory or clinical eventProductCommercial relevance
May 2024European Commission authorises OmlycloCT-P39First EU omalizumab biosimilar
March 2025FDA approves interchangeable Omlycloomalizumab-igecFirst U.S. approval
September 2025Amneal announces ADL-018 BLA filingADL-018Proposed U.S. entrant
October 2025EMA accepts AVT23 applicationAVT23Review underway; not approved
December 2025FDA approves 300 mg Omlyclo syringeOmlycloBroader presentation range
March 2026Teva applications accepted in U.S. and EUTeva candidateSecond-wave review
April 2026CuraTeQ reports Phase III BP11 findingsBP11Evidence for future submissions

The EMA’s 2024 assessment of Omlyclo found comparable structure, biological activity and clinical outcomes to Xolair. The FDA then granted interchangeability in March 2025 after reviewing biosimilarity evidence, including the chronic spontaneous urticaria program. Local prescribing information remains authoritative for patient age, indication and administration requirements.

Kashiv and its partners moved AVT23/ADL-018 through 2025 application milestones, while Teva reported accepted submissions in March 2026. CuraTeQ’s April 2026 positive Phase III findings are clinical data rather than a marketing decision. Any later authorisation would expand the number of approved suppliers, but patent settlements, manufacturing readiness and launch contracts may still determine timing. Alvotech’s 2025 financial disclosure attributed USD 23.6 million of milestones to the AVT23 confirmatory study and marketing application, illustrating why development receipts are separate from finished-product sales. The U.S. Omlyclo launch occurred more than eighteen months after the first European authorisation, making regulatory dates insufficient to predict first prescription revenue.

Competitive Landscape

Celltrion currently supplies the widely approved Omlyclo biosimilar, while multiple partnerships support investigational rivals. Market access is split among developers, manufacturers and local commercial licensees, so a company’s participation does not necessarily mean it books finished-product sales.

Marketed Supplier

Celltrion

Celltrion secured the first European approval in May 2024, FDA interchangeability in March 2025 and U.S. commercial availability in October 2026. Its portfolio now spans 75, 150 and 300 mg syringe strengths, with autoinjector options in selected countries. European distribution reached 26 countries by September 2026.

AVT23 Partnership

Kashiv, Alvotech and Advanz Pharma

Kashiv developed ADL-018 and submitted the U.S. application, while Alvotech and Advanz advanced European and UK reviews. The partnership divides clinical development, manufacturing and local commercial rights. Alvotech disclosed milestone receipts related to AVT23 submissions in its 2025 financial reporting.

U.S. Commercial Partner

Amneal Pharmaceuticals

Amneal holds U.S. rights to the Kashiv-developed omalizumab biosimilar. The company announced a September 2025 BLA submission and described U.S. Xolair reference sales above USD 4 billion over the preceding twelve months. Commercial sales of ADL-018 remain contingent on regulatory authorisation.

Pipeline Competitors

Teva and CuraTeQ Biologics

Teva’s omalizumab candidate entered FDA and EMA review in March 2026. CuraTeQ, an Aurobindo group company, announced Phase III comparability for BP11 in April 2026 after a trial across Europe and India. Neither March nor April 2026 development milestone granted an FDA or EMA marketing authorisation.

Alvotech’s October 2025 EMA filing acceptance demonstrates how European commercial rights can be shared among a developer and an established specialty-drug distributor. BiosanaPharma previously participated in AVT23 development through a continuous-manufacturing technology arrangement, while Kashiv’s regional agreements extend prospective reach into Latin America and Middle East markets. Contractual territories must be separated from countries where a product is already authorised.

A 2025 reference-product sales base above USD 4 billion in the United States provides a financial incentive for additional biosimilar applications, but competing developers face analytical comparability costs, patent risk and payer negotiation. Celltrion’s first-mover distribution network gives it an early commercial advantage; subsequent entrants may compete through net pricing, reliable supply, formulation choice and physician support rather than through novel mechanisms of action.

Key Companies Profiled

  • Celltrion, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Kashiv BioSciences LLC
  • Amneal Pharmaceuticals, Inc.
  • Alvotech
  • Advanz Pharma
  • CuraTeQ Biologics
  • BiosanaPharma

Recent Developments in the Omalizumab Biosimilars Market

October 2026: Celltrion began U.S. commercial distribution of Omlyclo on 5 October, following the FDA’s March 2025 interchangeability approval. The product launched in 75 mg, 150 mg and 300 mg syringe strengths for four reference-product indications. Pharmacy benefit access and prescriber familiarity now determine how quickly the first U.S. omalizumab biosimilar gains prescriptions. Source

August 2026: Celltrion launched the 300 mg Omlyclo presentation in Germany, the United Kingdom and France, adding both prefilled syringe and autoinjector choices. The company planned further European distribution during the second half of 2026. Higher-dose availability can reduce injection burden for selected regimens and strengthens the supplier’s national tender offering. Source

April 2026: CuraTeQ Biologics reported positive Phase III BP11 comparability results in 608 patients with chronic spontaneous urticaria across Europe and India. The company said its study met primary endpoints and supported planned FDA and EMA submissions. BP11 remained investigational at the announcement date, so the readout did not establish a marketed competitor. Source

March 2026: Teva announced that regulators in the United States and European Union had accepted applications for its proposed omalizumab biosimilar. The candidate entered formal review but had not received marketing authorisation in either region. The filings add prospective competition to Celltrion’s marketed Omlyclo franchise and may influence later payer negotiations. Source

December 2025: The FDA approved Celltrion’s 300 mg/2 mL Omlyclo prefilled syringe after its earlier 75 mg and 150 mg approvals. The expanded presentation range supports dosing flexibility for eligible asthma and allergic-disease patients. Celltrion identified the new strength as part of its U.S. commercial preparation, which culminated in the October 2026 launch. Source

October 2025: Alvotech and Advanz Pharma announced EMA acceptance of the AVT23 marketing application, following UK acceptance earlier in 2025. The Kashiv-developed candidate targets Xolair’s anti-IgE mechanism but remains subject to regulatory review. The application milestone extends prospective European supplier competition beyond the first approved Omlyclo product. Source

Market Outlook, 2026–2034

From the 2026 estimate of USD 683.2 million, the Omalizumab Biosimilars Market is forecast to reach USD 1.42 billion by 2034 at 9.6% CAGR, with further country launches and competing approvals offset by tender-led price compression.

Forecast variableDocumented 2025–2026 baselineLikely effect through 2034
Geographic rolloutOmlyclo in 26 European countries by September 2026Broader treatment access
U.S. accessOctober 2026 Omlyclo launchAdditional insured prescriptions
Device options300 mg and autoinjector expansionConvenience and tender differentiation
Competitive entriesAVT23 and Teva filings acceptedGreater pricing competition
Disease demandWHO 363 million asthma cases in 2023Large but eligibility-filtered patient pool
ProcurementEuropean tenders and U.S. formulary negotiationsLower net prices per injection

The European commercial footprint should remain the largest near-term source of routine biosimilar prescriptions because Omlyclo launched there before the United States. High-dose presentations and autoinjectors may support broader uptake among eligible patients, while tender procurement could transfer substantial volume from the originator to approved alternatives. The 2025 allocation therefore places Europe ahead of Asia-Pacific, with later North American growth linked to the October 2026 U.S. launch.

The U.S. reference-product category remains financially attractive, but payer rebates can absorb part of the benefit from higher treatment volumes. Celltrion entered U.S. distribution with interchangeability across four indications and multiple syringe strengths. Amneal’s proposed Kashiv product and Teva’s candidate could create additional bargaining options for insurers if authorised, yet the timing of their commercial entry depends on regulatory and intellectual-property outcomes.

New indications can change the eligible patient mix without changing the biosimilar’s molecular target. The FDA’s 2024 food-allergy expansion created a distinct U.S. treatment population, while severe asthma and chronic urticaria remain established uses. Local labels differ, so product developers must secure each jurisdiction’s appropriate authorisation before assuming the same indication mix or reimbursement access across countries.

The main constraints are manufacturing comparability, pharmacovigilance obligations, device training and price reductions after additional suppliers enter. Development milestones from AVT23 and BP11 demonstrate pipeline activity but are not proof of approved sales. The publisher-based USD 1.42 billion endpoint remains a forecast rather than an audited sum of company product disclosures, and actual revenue will depend on launch timing, net prices and patient persistence.

Report Coverage

Coverage spans approved anti-IgE biosimilar products, investigational candidates, delivery devices, treatment settings, national payer channels and country-level regulatory status.

Market Sizing & ForecastPublisher 2025 and 2034 endpoints, 2026 estimate and 2026–2034 annualised growth.
SegmentationDelivery Presentation, Therapeutic Indication, Treatment Setting and Procurement Channel.
Regional AnalysisFive regions and documented launches or licensing arrangements in selected countries.
Competitive LandscapeCelltrion marketed product and seven verified in-scope development or commercial partners.
Regulatory & AccessFDA, EMA, TGA and country-specific authorisations, substitution and reimbursement.
Market DynamicsGrowth drivers, restraints and signed CAGR contribution analysis.

Frequently Asked Questions

What is the size of the Omalizumab Biosimilars Market in 2025?

The publisher-defined market value is **USD 623.5 million in 2025**. The category includes approved omalizumab biosimilar supply and identifiable in-scope commercial development receipts, not Xolair originator sales. Celltrion’s Omlyclo is the principal approved product, while other candidates were progressing through regulatory review during 2025–2026.

How fast will the omalizumab biosimilars market grow through 2034?

The forecast uses a **9.6% CAGR for 2026–2034**, reaching USD 1.42 billion in 2034 from a 2026 estimate of USD 683.2 million. The 9.6% annualised rate follows the 2025 and 2034 publisher monetary endpoints. Geographic launches and new suppliers support volume, while payer discounts constrain revenue per injection.

Which omalizumab biosimilar is approved by the FDA?

Omlyclo (omalizumab-igec) from Celltrion received FDA approval and interchangeability in March 2025. The initial U.S. 75 mg and 150 mg syringes were followed by a 300 mg presentation in December. Celltrion announced commercial U.S. availability on 5 October 2026 for the reference product’s four U.S. indications.

Is Omlyclo interchangeable with Xolair in the United States?

Yes. The FDA designated Omlyclo interchangeable with reference Xolair in March 2025. Pharmacy substitution nevertheless follows state law, prescriber instructions and payer requirements. Clinical assessment remains important because omalizumab carries an anaphylaxis warning and treatment is not an emergency substitute for epinephrine in food-allergy reactions.

Which region leads the Omalizumab Biosimilars Market?

Europe leads the private 2025 allocation at an estimated **~51% of revenue**. Omlyclo obtained EU authorisation in May 2024 and began commercial availability in Norway in September 2025. Celltrion subsequently expanded distribution and launched a 300 mg presentation in major European markets during 2026.

Are there biosimilars to Xolair other than Omlyclo?

Several alternatives are in development, but filing acceptance is not marketing approval. Kashiv’s ADL-018/AVT23 entered U.S. and European review, Teva announced accepted FDA and EMA submissions in March 2026, and CuraTeQ reported positive BP11 Phase III results in April. The launch timing for ADL-018, Teva’s candidate and BP11 depends on subsequent FDA or EMA decisions.

What conditions are treated with omalizumab biosimilars?

U.S. Omlyclo indications include allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis with nasal polyps and IgE-mediated food allergy. European and Japanese labels have different age or indication details. Clinicians should use the local approved prescribing information rather than assume that every biosimilar carries identical authorisations worldwide.

Can omalizumab biosimilars be injected at home?

Some patients may self-administer after appropriate clinical assessment and training under their local product label. Celltrion expanded prefilled-syringe strengths and autoinjector availability in 2025–2026, which may reduce clinic visits for suitable patients. Initial supervision and anaphylaxis precautions remain important, especially for patients with severe allergic disease.

Who are the main omalizumab biosimilar companies?

Celltrion markets Omlyclo, while Kashiv, Alvotech, Advanz Pharma and Amneal participate in the ADL-018/AVT23 program. Teva has an independently filed candidate, CuraTeQ is developing BP11, and BiosanaPharma participated in an earlier manufacturing-development agreement. These roles include clinical development and licensing, not only finished-drug sales.

What limits adoption of omalizumab biosimilars?

National tender discounts, patent questions, pharmacy-substitution rules and clinical monitoring requirements can slow commercial conversion after approval. Omalizumab also has an anaphylaxis warning, requiring patient education and observation practices. Developers must maintain comparable product quality and reliable cold-chain supply to win hospital and specialty-pharmacy contracts.

What is the 2034 outlook for omalizumab biosimilar treatments?

The forecast reaches **USD 1.42 billion in 2034**, supported by expanded Omlyclo supply and potential approvals for competing candidates. U.S. formulary access and European tenders will influence the balance between prescription growth and net pricing. Clinical use will remain tied to approved indications and eligibility for anti-IgE treatment.

Research Sources & Evidence Base

View research sources used for this overview
  1. European Medicines Agency. Omlyclo EPAR and authorisation, May 2024.
  2. U.S. Food and Drug Administration. Omlyclo interchangeability approval letter, March 2025.
  3. U.S. Food and Drug Administration. Xolair IgE-mediated food allergy approval, February 2024.
  4. World Health Organization. Asthma global fact sheet, April 2026.
  5. Therapeutic Goods Administration. Omlyclo Australian registration, November 2024.
  6. Celltrion USA. U.S. approval of Omlyclo, March 2025.
  7. Celltrion USA. U.S. commercial launch of Omlyclo, October 2026.
  8. Celltrion USA. FDA 300 mg Omlyclo approval, December 2025.
  9. Celltrion. European Omlyclo launch, September 2025.
  10. Celltrion. European 300 mg Omlyclo launch, August 2026.
  11. Celltrion. European Commission 300 mg line extension, November 2025.
  12. Celltrion. Japan Omlyclo marketing approval, March 2026.
  13. Celltrion. Brazil Omlyclo launch, November 2025.
  14. Celltrion. Canadian 300 mg presentations, January 2026.
  15. Teva Pharmaceutical Industries. FDA and EMA filing acceptance for omalizumab biosimilar, March 2026.
  16. Amneal Pharmaceuticals. ADL-018 FDA BLA submission, September 2025.
  17. Amneal Pharmaceuticals. Kashiv ADL-018 confirmatory study results, June 2025.
  18. Alvotech. AVT23 EMA application accepted, October 2025.
  19. Alvotech. AVT23 UK application accepted, March 2025.
  20. Alvotech. 2025 AVT23 development milestone disclosures, November 2025.
  21. Kashiv BioSciences. Regional ADL-018 licensing and development news, August–October 2025.
  22. Novartis. 2025 Xolair product revenue, February 2026.
  23. CuraTeQ Biologics. Company biosimilar pipeline and clinical development, 2026.
  24. Alvotech. AVT23 development partnership with BiosanaPharma, February 2022.
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-15053
Base Year See report overview
Forecast Period See report overview
Last Updated 26 Oct 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.